Numinus Wellness Inc. announced that its research site, Cedar Clinical Research ("CCR"), has been chosen as one of multiple sites for Cybin's Phase 3 pivotal, multinational clinical trial of CYB003 for the adjunctive treatment of Major Depressive Disorder ("MDD"). In its recently completed Phase 2 trial in participants with moderate to severe major depressive disorder, Cybin reported that at four months after dosing, 75% of patients receiving two 16mg doses of CYB003 achieved remission from depression symptoms. With the Phase 2 trial data, the U.S. Food and Drug Administration ("FDA") granted CYB003 breakthrough therapy designation, potentially shortening the drug development timeline. The Phase 3 trial for CYB003 is planned to commence enrollment mid-2024 and focus on its safety and efficacy.CCR's Murray, Utah, location will be one of the 15 U.S. sites.

Dr. Paul Thielking, Chief Science Officer of Numinus, will be the Principal Investigator.